Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.
Mechelen, BE
Size (employees)
278 (est)
Biocartis was founded in 2007 and is headquartered in Mechelen, BE
Report incorrect company information

Key People/Management at Biocartis

Ulrik Cordes

Ulrik Cordes

Chief Commercial Officer
Chris Gabriels

Chris Gabriels

Director of Operations

Biocartis Office Locations

Biocartis has an office in Mechelen
Mechelen, BE (HQ)
11 Generaal de Wittelaan
Show all (1)
Report incorrect company information

Biocartis Financials and Metrics

Biocartis Financials

Market capitalization (22-Mar-2017)

440.5 b

Closing share price (22-Mar-2017)

Biocartis's current market capitalization is €440.5 b.
Show all financial metrics
Report incorrect company information

Biocartis News and Updates

New Report Focusing on Liquid Biopsy Products Market CAGR of +23% during the Forecast Period: Regulative Landscape, Newly Invented Strategies, Statistical Investigation, And Key Players Like RainDanceTechnologies, Biocartis, Qiagen, Guardant

Factors such as increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased…
Report incorrect company information